Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
January 12, 2026 08:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Kailera announced the first participants randomized in the global Phase 3 clinical program of GLP-1/GIP receptor dual agonist ribupatide (KAI-9531).
April 26, 2025 14:09 ET | Source: Sesame

Sesame Care Under Review: The Success by Sesame Weight Loss Medication Program with Compounded Semaglutide Prescription

New York, April 26, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why traditional weight loss methods fail to deliver sustainable results—and how Success by Sesame aims to solve...